Literature DB >> 3155687

Enhancement of human B cell proliferation by an antibody to the C3d receptor, the gp 140 molecule.

R Frade, M C Crevon, M Barel, A Vazquez, L Krikorian, C Charriaut, P Galanaud.   

Abstract

The C3d receptor is a specific marker of B lymphocytes. Recently we have shown that C3d receptor activity is carried by a gp 140 membrane antigen. A polyclonal antibody has been prepared by immunizing a rabbit with highly purified gp 140 molecule isolated from membranes of the human B lymphoblastoid cell line Raji and its high specificity was previously demonstrated. We tested the effect of this antibody to the C3d receptor on the B cell proliferative response. Purified B cells from human blood were induced to proliferate by a B cell growth factor (BCGF)-containing partially purified supernatant from activated T cells. The anti-C3d receptor F(ab')2 enhanced the BCGF-dependent B cell proliferation. This effect was dose dependent, was observed in the presence of different concentrations of BCGF and did not correspond to a change in the time course of the response. The anti-C3d receptor F(ab')2 had no mitogenic effect in the absence of T cell supernatant. In contrast the undigested anti-C3d receptor IgG suppressed the BCGF-dependent B cell proliferation. These results emphasize the potentialities of anti-gp 140 F(ab')2 to explore the involvement of the C3d receptor in the regulation of B cell response to T cell products.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 3155687     DOI: 10.1002/eji.1830150114

Source DB:  PubMed          Journal:  Eur J Immunol        ISSN: 0014-2980            Impact factor:   5.532


  30 in total

1.  Epstein-Barr virus (EBV) induces expression of B-cell activation markers on in vitro infection of EBV-negative B-lymphoma cells.

Authors:  A Calender; M Billaud; J P Aubry; J Banchereau; M Vuillaume; G M Lenoir
Journal:  Proc Natl Acad Sci U S A       Date:  1987-11       Impact factor: 11.205

Review 2.  Epstein-Barr virus tissue tropism: a major determinant of immunopathogenesis.

Authors:  L Hutt-Fletcher
Journal:  Springer Semin Immunopathol       Date:  1991

3.  Mapping of the C3d receptor (CR2)-binding site and a neoantigenic site in the C3d domain of the third component of complement.

Authors:  J D Lambris; V S Ganu; S Hirani; H J Müller-Eberhard
Journal:  Proc Natl Acad Sci U S A       Date:  1985-06       Impact factor: 11.205

Review 4.  Functional B-lymphocyte surface antigens.

Authors:  J T Golay
Journal:  Immunology       Date:  1986-09       Impact factor: 7.397

5.  Stable transfection of Epstein-Barr virus (EBV) nuclear antigen 2 in lymphoma cells containing the EBV P3HR1 genome induces expression of B-cell activation molecules CD21 and CD23.

Authors:  M Cordier; A Calender; M Billaud; U Zimber; G Rousselet; O Pavlish; J Banchereau; T Tursz; G Bornkamm; G M Lenoir
Journal:  J Virol       Date:  1990-03       Impact factor: 5.103

6.  Epstein-Barr virus/complement fragment C3d receptor (CR2) reacts with p53, a cellular antioncogene-encoded membrane phosphoprotein: detection by polyclonal anti-idiotypic anti-CR2 antibodies.

Authors:  M Barel; A Fiandino; F Lyamani; R Frade
Journal:  Proc Natl Acad Sci U S A       Date:  1989-12       Impact factor: 11.205

7.  Molecular cloning of the cDNA encoding the Epstein-Barr virus/C3d receptor (complement receptor type 2) of human B lymphocytes.

Authors:  M D Moore; N R Cooper; B F Tack; G R Nemerow
Journal:  Proc Natl Acad Sci U S A       Date:  1987-12       Impact factor: 11.205

8.  Synergistic activation of cells by Epstein-Barr virus and B-cell growth factor.

Authors:  L M Hutt-Fletcher
Journal:  J Virol       Date:  1987-03       Impact factor: 5.103

9.  Control of human B-lymphocyte replication. II. Transforming Epstein-Barr virus exploits three distinct viral signals to undermine three separate control points in B-cell growth.

Authors:  J Gordon; L Walker; G Guy; G Brown; M Rowe; A Rickinson
Journal:  Immunology       Date:  1986-08       Impact factor: 7.397

10.  Structural and functional analysis of CR2/EBV receptor by means of monoclonal antibodies and limited tryptic digestion.

Authors:  A L Petzer; T F Schulz; R Stauder; A Eigentler; B L Myones; M P Dierich
Journal:  Immunology       Date:  1988-01       Impact factor: 7.397

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.